ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

被引：0
|
作者：
McEwan, P. [1 ]
Evans, L. M. [2 ]
Bergenheim, K. [3 ]
机构：
[1] CRC, Cardiff, S Glam, Wales
[2] Univ Wales Hosp, Cardiff, Vale Glamorga, Wales
[3] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72108-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A293 / A293
页数：1
相关论文
共 50 条
  • [41] Therapeutic Intensification Strategy and Incident Cardiovascular Disease (CVD) in Type 2 Diabetes Mellitus (T2DM)
    Korytkowski, Mary T.
    Brooks, Maria M.
    Orchard, Trevor J.
    Dealmeida, Dilhari
    Lombardero, Manuel
    Kanter, Justin
    Siminerio, Linda M.
    DIABETES, 2014, 63 : A118 - A118
  • [42] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
  • [43] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [44] Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
    Michael Willis
    Adam Fridhammar
    Jens Gundgaard
    Andreas Nilsson
    Pierre Johansen
    PharmacoEconomics, 2020, 38 : 953 - 969
  • [45] Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
    Willis, Michael
    Fridhammar, Adam
    Gundgaard, Jens
    Nilsson, Andreas
    Johansen, Pierre
    PHARMACOECONOMICS, 2020, 38 (09) : 953 - 969
  • [46] COST-EFFECTIVENESS OF USING DETEMIR IN TYPE 2 DIABETES WITH THE RISK OF CARDIOVASCULAR EVENTS AND DEATH
    Romero, M.
    Chavez, D.
    Karpf, E.
    Alvis, N.
    VALUE IN HEALTH, 2011, 14 (07) : A547 - A547
  • [47] MicroRNAs as biomarkers for monitoring cardiovascular changes in Type II Diabetes Mellitus (T2DM) and exercise
    Volga M Saini
    Kaitlyn R. Liu
    Aishwarya Suryakant Surve
    Sanjeev Gupta
    Ananya Gupta
    Journal of Diabetes & Metabolic Disorders, 2022, 21 : 1819 - 1832
  • [48] COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY
    Jozsa, Z.
    Toth, E.
    Nagy, B.
    VALUE IN HEALTH, 2010, 13 (07) : A289 - A289
  • [49] MicroRNAs as biomarkers for monitoring cardiovascular changes in Type II Diabetes Mellitus (T2DM) and exercise
    Saini, Volga M.
    Liu, Kaitlyn R.
    Surve, Aishwarya Suryakant
    Gupta, Sanjeev
    Gupta, Ananya
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2022, 21 (02) : 1819 - 1832
  • [50] Mechanism of metabolic surgery for the treatment of Type 2 Diabetes Mellitus (T2DM)
    Leishman, David J.
    Ikramuddin, Sayeed
    Naitoh, Takeshi
    MINI-INVASIVE SURGERY, 2023, 7
12345